Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
Zelniker TA, Ruff CT, Wiviott SD, Blanc JJ, Cappato R, Nordio F, Mercuri MF, Lanz H, Antman EM, Braunwald E, Giugliano RP. Zelniker TA, et al. Among authors: nordio f. Eur Heart J Acute Cardiovasc Care. 2019 Mar;8(2):176-185. doi: 10.1177/2048872618790561. Epub 2018 Jul 24. Eur Heart J Acute Cardiovasc Care. 2019. PMID: 30039978 Clinical Trial.
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.
Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Mega JL, et al. Among authors: nordio f. Lancet. 2015 Jun 6;385(9984):2264-2271. doi: 10.1016/S0140-6736(14)61730-X. Epub 2015 Mar 4. Lancet. 2015. PMID: 25748612 Free PMC article.
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A, Giugliano RP, Ruff CT, Nordio F, Gogia HS, Awasty VR, Henderson DA, Mercuri MF, Rutman H, Antman EM, Braunwald E. Eisen A, et al. Among authors: nordio f. Am Heart J. 2016 Feb;172:144-51. doi: 10.1016/j.ahj.2015.11.004. Epub 2015 Dec 1. Am Heart J. 2016. PMID: 26856226 Clinical Trial.
Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48.
Plitt A, Ezekowitz MD, De Caterina R, Nordio F, Peterson N, Giugliano RP; ENGAGE AF-TIMI 48 Investigators. Plitt A, et al. Among authors: nordio f. Clin Cardiol. 2016 Jun;39(6):345-6. doi: 10.1002/clc.22537. Epub 2016 Mar 30. Clin Cardiol. 2016. PMID: 27028520 Free PMC article. Clinical Trial. No abstract available.
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M, Moccetti T, Mitrovic V, Shi M, Mercuri M, Antman EM, Braunwald E. Magnani G, et al. Among authors: nordio f. Eur J Heart Fail. 2016 Sep;18(9):1153-61. doi: 10.1002/ejhf.595. Epub 2016 Jun 28. Eur J Heart Fail. 2016. PMID: 27349698 Free article. Clinical Trial.
59 results